182223-54-7

Basic information

• Product Name: 4-Cbz-Aminopiperidine
• Synonyms: benzyl piperidin-4-ylcarbamate hydrochloride;N-CBZ-piperidin-4-aMine;benzyl N-(piperidin-4-yl)carbaMate;Carbamic acid, 4-piperidinyl-, phenylmethyl ester;4-CBZ-AMINOPIPERIDINE;4-BENZYLOXYCARBONYLAMINO-PIPERIDINE;Carbamic acid, 4-piperidinyl-, phenylmethyl ester (9CI);4-Benzyloxycarbonylamino-piperdine
• CAS NO: 182223-54-7
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.29
• Product Categories: N-CBZ;pharmacetical;API intermediates
• Mol File: 182223-54-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 396.3 °C at 760 mmHg
• Flash Point: 193.475 °C
• Appearance: /
• Density: 1.139 g/cm³
• Vapor Pressure: 1.73E-06mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Dichloromethane
• PKA: 12.18±0.20(Predicted)
• CAS DataBase Reference: 4-Cbz-Aminopiperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cbz-Aminopiperidine(182223-54-7)
• EPA Substance Registry System: 4-Cbz-Aminopiperidine(182223-54-7)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 182223-54-7(Hazardous Substances Data)

Usage

Uses

4-Benzyloxycarbonylaminopiperidine is an intermediate in synthesizing 7-Ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin (E899150), a major metabolite of Irinotecan.

InChI:InChI=1/C13H18N2O2/c16-13(15-12-6-8-14-9-7-12)17-10-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2,(H,15,16)

Upstream product

• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 501-53-1 benzyl chloroformate 
• 220394-97-8 4-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)piperidine 
• 182223-53-6 benzyl 1-benzylpiperidin-4-ylcarbamate 

Downstream Products

• 910858-80-9 {1-[(2R)-2-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-piperidin-4-yl}-carbamic acid benzyl ester 
• 1427058-44-3 1-(2-fluoropentyl)piperidin-4-amine 
• 1306720-02-4 [1-(4-acryloylaminobenzenesulfonyl)piperidin-4-yl]carbamic acid benzyl ester 
• 1306723-06-7 [1-(4-aminobenzenesulfonyl)piperidin-4-yl]carbamic acid benzyl ester 
• 1306723-05-6 [1-(4-nitrobenzenesulfonyl)piperidin-4-yl]carbamic acid benzyl ester 
• 1187321-38-5 2,3:4,5-di-O-isopropylidene-1-[4-(benzyloxycarbonylamino)-piperidin-1-yl]-1-deoxy-β-D-fructopyranose 
• 1187321-81-8 C₂₆H₃₆N₂O₉ 
• 1187321-61-4 C₂₆H₃₆N₂O₉ 
• 1072828-03-5 [1-(3-fluoro-6-methoxy-[1,5]naphthyridin-4-yl)-piperidin-4-yl]-carbamic acid benzyl ester 
• 402927-96-2 C₁₄H₂₀N₂O₄S 

Relevant articles and documents

COMPOUND WITH ANTICANCER ACTIVITY

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

2,4-disubstituted [...] compound, and its preparation, and pharmaceutical composition and use thereof

The invention discloses new 2,4-disubstituted quinazoline compounds and a preparation method, a medicinal composition and application thereof. The invention particularly relates to 2,4-disubstituted quinazoline compounds shown as a general formula I, medicinal salts thereof, precursors or derivatives thereof with the same biological function, a preparation method thereof, a composition containing one or more of the compounds, and application of the compounds in inhibiting activity of Pin1 enzyme, inhibiting activity of tumor growth and the like.

PYRROLIDIN-3-YLACETIC ACID DERIVATIVE

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a C3-8 cycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a C3-8 cycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a C1-6 alkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a C1-6 alkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.